SLA/ maladie de Charcot/biomarqueurs/omiques/ TDP43
Use of metabolomics strategy in Amyotrophic Lateral Sclerosis (patients, animal and cell models): (i) to identify diagnostic and prognostic biomarkers; (ii) to explore pathophysiological mechanisms; and (iii) to evaluate the effects of drugs.
Development of IA methods to optimize the use of heath data from routine and research to help in diagnosis and prognosis ( région CVL support)
Development of innovative therapeutic approaches based on biopharmaceuticals (LabEx MabImprove) targeting TDP-43 in ALS